Superluminal Medicines: Funding, Investors & Team (Sep 2026)
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a combination of biology, chemistry, machine learning, and big data analysis. By using advanced computational and machine-learning techniques, they are able to identify and optimize potential drug candidates more quickly and efficiently than traditional methods. Their approach combines experimental data with algorithms to expedite the discovery of therapeutic compounds.
Superluminal Medicines has raised $185M across 3 funding rounds on record, the most recent a Series B of $65.5M announced in Sep 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Superluminal Medicines Company Profile and Key Stats
Latest funding round on record: Sep 2026.
Superluminal Medicines Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Superluminal Medicines raised $120M in a Series A announced in Sep 2024.
11 months later, an undisclosed round was announced in Aug 2025 with no disclosed amount.
1.1 years later, a Series B of $65.5M was announced in Sep 2026.
Superluminal Medicines Investors
12 investors are recorded in total; the 5 named above are those the record identifies.
Superluminal Medicines Founders and Leadership Team
Contact details for the Superluminal Medicines team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Superluminal Medicines Funding Compared to Other Biotechnology Startups
Superluminal Medicines' latest round of $65.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Superluminal Medicines in Biotechnology and Boston
Companies Similar to Superluminal Medicines
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Superluminal Medicines Funding FAQs
What does Superluminal Medicines do?
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a combination of biology, chemistry, machine learning, and big data analysis. By using advanced computational and machine-learning techniques, they are able to identify and optimize potential drug candidates more quickly and efficiently than traditional methods. Their approach combines experimental data with algorithms to expedite the discovery of therapeutic compounds.
How much funding has Superluminal Medicines raised?
Superluminal Medicines has raised $185M across 3 rounds on record. The most recent is a Series B of $65.5M announced in Sep 2026.
When did Superluminal Medicines last raise funding?
Superluminal Medicines' most recent funding round on record is a Series B of $65.5M, announced in Sep 2026.
Who has invested in Superluminal Medicines?
Investors on record for Superluminal Medicines include RA Capital Management, NVIDIA, Insight Partners, Gaingels, Eli Lilly. FundedIQ records 12 investors in total.
Who founded Superluminal Medicines?
FundedIQ lists Ajay Yekkirala (Co-founder & Chief Scientific Officer), Cony D'cruz (Founder) at Superluminal Medicines.
Where is Superluminal Medicines headquartered?
Superluminal Medicines is based in Boston, Massachusetts, United States.
How many employees does Superluminal Medicines have?
Superluminal Medicines is in the 11-50 employee band.
When was Superluminal Medicines founded?
Superluminal Medicines was founded in 2022.
How does Superluminal Medicines' funding compare to other Biotechnology startups?
Superluminal Medicines' latest round of $65.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Superluminal Medicines Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Superluminal Medicines is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.